Thalidomide effect in endothelial cell of the acute radiation proctitis

World Journal of Gastroenterology

Volumn 14, Issue 30, 2008, Pages 4779-4783

  Kim, Ki Tae ^a   Chae, Hiun Suk ^a,b   Kim, Jin Soo ^a   Kim, Hyung Keun ^a   Cho, Young Seok ^a   Choi, Whang ^a   Choi, Kyu Yong ^a   Rho, Sang Young ^a   Kang, Suk Jin ^a  

^a The Catholic University of Korea   (South Korea)

^b Uijeongbu St Mary's Hospital   (South Korea)

Author keywords

Radiation proctitis; Thalidomide; Thrombomodulin; Vascular endothelial growth factor; Von Willebrand factor

Indexed keywords

THALIDOMIDE; THROMBOMODULIN; VASCULOTROPIN; VON WILLEBRAND FACTOR; RADIOPROTECTIVE AGENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; NONHUMAN; PROCTITIS; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIATION INJURY; RAT; TREATMENT DURATION; ANIMAL; DRUG EFFECT; METABOLISM; MICROCIRCULATION; PATHOLOGY; RECTUM; WISTAR RAT;

ANIMALS; ENDOTHELIAL CELLS; FEMALE; MICROCIRCULATION; PROCTITIS; RADIATION INJURIES, EXPERIMENTAL; RADIATION-PROTECTIVE AGENTS; RATS; RATS, WISTAR; RECTUM; THALIDOMIDE; THROMBOMODULIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 55449115376     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4779     Document Type: Article

References (33)

1. Hauer-Jensen M, Fink LM, Wang J. Radiation injury and the protein C pathway. Crit Care Med 2004; 32: S325-S330
2. Boerma M, Kruse JJ, van Loenen M, Klein HR, Bart CI, Zurcher C, Wondergem J. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Strahlenther Onkol 2004; 180: 109-116
3. Wang J, Boerma M, Fu Q, Hauer-Jensen M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol 2007; 13: 3047-3055
4. Molla M, Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol 2007; 13: 3043-3046
5. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-1383
6. Richter KK, Fink LM, Hughes BM, Sung CC, Hauer-Jensen M. Is the loss of endothelial thrombomodulin involved in the mechanism of chronicity in late radiation enteropathy? Radiother Oncol 1997; 44: 65-71
7. Scaldaferri F, Sans M, Vetrano S, Graziani C, De Cristofaro R, Gerlitz B, Repici A, Arena V, Malesci A, Panes J, Grinnell BW, Danese S. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest 2007; 117: 1951-1960
8. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610
9. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008; 27: 111-135
10. Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, Silv F, Pereira Junior FA, Pereira MG, Tortori C, Dines I, Carvalho J, Rocha E, Elia C. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J Gastroenterol 2007; 13: 2166-2173
11. Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 2007; 25: 557-567
12. Komorowski J, Jerczyńska H, Siejka A, Barańska P, Ławnicka H, Pawłowska Z, Stepień H. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci 2006; 78: 2558-2563
13. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 515-523
14. Chidlow JH Jr, Langston W, Greer JJ, Ostanin D, Abdelbaqi M, Houghton J, Senthilkumar A, Shukla D, Mazar AP, Grisham MB, Kevil CG. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169: 2014-2030
15. Taha Y, Raab Y, Larsson A, Carlson M, Loof L, Gerdin B, Thorn M. Vascular endothelial growth factor (VEGF) - a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci 2004; 49: 109-115
16. Northway MG, Scobey MW, Geisinger KR. Radiation proctitis in the rat. Sequential changes and effects of anti-inflammatory agents. Cancer 1988; 62: 1962-1969
17. Smith JM, Meinkoth JH, Hochstatter T, Meyers KM. Differential distribution of von Willebrand factor in canine vascular endothelium. Am J Vet Res 1996; 57: 750-755
18. Weidner N, Gasparini G. Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res Treat 1994; 29: 97-107
19. Rübe CE, Rodemann HP, Rübe CE. [The relevance of cytokines in the radiation-induced lung reaction. Experimental basis and clinical significance] Strahlenther Onkol 2004; 180: 541-549
20. Linard C, Marquette C, Mathieu J, Pennequin A, Clarennon D, Mathe D. Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: effect of an NF-kappaB inhibitor. Int J Radiat Oncol Biol Phys 2004; 58: 427-434
21. Rodel F, Hantschel M, Hildebrandt G, Schultze-Mosgau S, Rodel C, Herrmann M, Sauer R, Voll RE. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kappaB) in EA.hy.926 endothelial cells after low-dose X-irradiation. Int J Radiat Biol 2004; 80: 115-123
22. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002; 168: 2644-2651
23. Bowcock SJ, Rassam SM, Ward SM, Turner JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7: 51-53
24. Corso A, Lorenzi A, Terulla V, Airo F, Varettoni M, Mangiacavalli S, Zappasodi P, Rusconi C, Lazzarino M. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83: 588-591
25. Petropoulou AD, Gerotziafas GT, Samama MM, Hatmi M, Rendu F, Elalamy I. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res 2008; 121: 493-497
26. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508-515
27. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-265
28. Pearson JD. Markers of endothelial perturbation and damage. Br J Rheumatol 1993; 32: 651-652
29. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, Dewhirst MW, Haroon ZA. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 2001; 50: 851-855
30. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 2002; 30: 173-177
31. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by upregulation of its receptors. J Biol Chem 1999; 274: 23969-23976
32. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993; 264: C1302-C1307
33. Koukourakis MI, Flordellis CS, Giatromanolaki A, Koukouraki S, Kapsoritakis A, Potamianos S, Retalis G, Sivridis E, Salsaa B, Harris AL, Maragoudakis MI. Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis. Clin Cancer Res 1999; 5: 3970-3976